BROOKLYN, New York, Oct. 14, 2020 (GLOBE NEWSWIRE) -- According to the new report published by Global Market Estimates, the Pantoprazole API Market will rise at a CAGR assessment of 3.2% during the figure season of 2020-2026. One of the most common proton pump inhibitors in the market is Pantoprazole API, which is used to address diseases of the gastroenterology. The mode of action involves acting upon the amount of acid released in the stomach to avoid further digestive damage. The FDA approved an indication of this drug is the treatment of erosive esophagitis, pathological hypersecretory conditions i.e. Zollinger-Ellison syndrome, and heartburn issues such as GERD for patients undergoing the parallel treatment process. Amongst all the indications, GERD is a highly incident disorder, which is why the market of Pantoprazole API will grow faster during the forecast period. Moreover, the availability of the types of oral drugs as per the patient requirements will help the market to grow.
Browse 159 Market Data Tables and 175 Figures spread through 281 Pages on "Global Pantoprazole API Market - Forecasts to 2026" https://www.globalmarketestimates.com/market-report/global-pantoprazole-api-market-2349
By Type of Drug (Generic & Brand), By Type of Dosage (20 mg & 40 mg), By Route of Administration (Oral [Delayed Release Tablets, Enteric Coated Tablets] & Intravenous), By Indication (Gastroenterology [GERD, Erosive Esophagitis and Hypersecretory conditions including Zollinger-Ellison Syndrome]), By Region (Asia Pacific, MEA, CSA, North America, and Europe), Company Market Share & Competitor Analysis
Key Market Insights:
- The Pantoprazole API Market will rise at a CAGR assessment of 3.2% during the figure season of 2020-2026.
- Based on the prescription data analysis for Pantoprazole, the generic version of this drug will have more market share than the branded version.
- The Pantoprazole API is the first line of treatment for Gastroesophageal reflux disease or GERD, hence making this application segment to be the largest in the market
- The Asia Pacific will predict an ascent in its market development because of rising cases of gastroenterology related diseases
Major companies in the market are Actavis (TEVA), Nora Pharma, GSK, Apotex Corporation, Angita Pharma, Mantra Pharma, Ahn-Gook Pharmal, Auro Pharma, Eurofarma Laboratorios, Abbott, Akeda, Devonian, Zydus Pharmaceuticals, Huarun Shuanghe Pharmaceutical, Northeast Pharmaceutical, Nanjing Yiheng Pharmaceutical, NCPC, Torrent Pharma, Nanjing Changao Pharmaceutical, Harbin Yuheng Pharmaceutical, Shanghai AIDEFA Pharmaceutical, Sinopharm Group, Wuxi Kaifu Pharmaceutical, Yangzijiang Pharmaceutical, and Chengdu Baiyu Pharmaceutical among others.
Browse the Global Pantoprazole API Market Report at https://www.globalmarketestimates.com/market-report/global-pantoprazole-api-market-2349
- Type of Drug Outlook (Revenue, USD Million, 2020 - 2026)
- Generic
- Brand
- Type of Dosage Outlook (Revenue, USD Million, 2020 - 2026)
- 20 mg
- 40 mg
- Route of Administration Outlook (Revenue, USD Million, 2020 - 2026)
- Oral
- Delayed-Release Tablets
- Enteric Coated Tablets
- Intravenous
- Oral
- Type of Indication Outlook (Revenue, USD Million, 2020 - 2026)
- Gastroenterology
- GERD
- Erosive Esophagitis
- Hypersecretory conditions including Zollinger-Ellison Syndrome
- Gastroenterology
- Regional Outlook (Revenue, USD Million, 2020 - 2026)
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of APAC
- Central & South America
- Brazil
- Argentina
- Chile
- Rest of CSA
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
- North America
Contact: Yash Jain
Email address: sales@globalmarketestimates.com
Phone Number: +16026667238
Website: https://www.globalmarketestimates.com/
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php